CURAS Stock Overview
A biotech company, develops treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Curasight A/S Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | DKK 2.10 |
| 52 Week High | DKK 16.90 |
| 52 Week Low | DKK 2.04 |
| Beta | -0.0049 |
| 1 Month Change | -65.80% |
| 3 Month Change | -77.32% |
| 1 Year Change | -80.00% |
| 3 Year Change | -82.44% |
| 5 Year Change | n/a |
| Change since IPO | -89.66% |
Recent News & Updates
Shareholder Returns
| CURAS | SE Biotechs | SE Market | |
|---|---|---|---|
| 7D | -7.5% | -1.7% | -0.4% |
| 1Y | -80.0% | -3.0% | -5.1% |
Return vs Industry: CURAS underperformed the Swedish Biotechs industry which returned -1.9% over the past year.
Return vs Market: CURAS underperformed the Swedish Market which returned -3.8% over the past year.
Price Volatility
| CURAS volatility | |
|---|---|
| CURAS Average Weekly Movement | 19.7% |
| Biotechs Industry Average Movement | 9.3% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in SE Market | 13.6% |
| 10% least volatile stocks in SE Market | 4.2% |
Stable Share Price: CURAS's share price has been volatile over the past 3 months compared to the Swedish market.
Volatility Over Time: CURAS's weekly volatility has increased from 14% to 20% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 4 | Ulrich Krasilnikoff | www.curasight.com |
Curasight A/S, a biotech company, develops treatment of cancer. The company exploits a novel Positron Emissions Tomography (PET) imaging platform that targets the urokinase-type plasminogen activator receptor (uPAR). It develops uTRACE for enhanced evaluation of cancer disease across several cancer types has been confirmed in multiple phase II clinical trials; and uTREAT, a uPAR targeted radionuclide therapy is using uTRACE together with radiation therapy to irradiate cancer with limited irradiation of healthy tissue.
Curasight A/S Fundamentals Summary
| CURAS fundamental statistics | |
|---|---|
| Market cap | DKK 44.41m |
| Earnings (TTM) | -DKK 34.05m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-1.3x
P/E RatioIs CURAS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CURAS income statement (TTM) | |
|---|---|
| Revenue | DKK 0 |
| Cost of Revenue | DKK 30.05m |
| Gross Profit | -DKK 30.04m |
| Other Expenses | DKK 4.00m |
| Earnings | -DKK 34.05m |
Last Reported Earnings
Mar 31, 2025
Next Earnings Date
May 13, 2025
| Earnings per share (EPS) | -1.61 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 448.9% |
How did CURAS perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/05/09 21:01 |
| End of Day Share Price | 2025/05/09 00:00 |
| Earnings | 2025/03/31 |
| Annual Earnings | 2024/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Curasight A/S is covered by 1 analysts. 1 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Fredrik Thor | Redeye |